These trials, which are estimated to complete in 2027, include its use as monotherapy in adults with type 1 diabetes mellitus (T1DM)
In the SURMOUNT-1 trial, nausea rates were 24% at the 5mg dose, 24% at 10mg, and 24% at 15mg vs 9.5% with placebo (Jastreboff et al., 2022)
In contrast, Wegovy users lost about 13.7% of their body weight in the same period
Everything the B12 injection does, plus fat metabolism support, liver function optimization, and insulin sensitization
5 But getting started, and staying consistent, can feel overwhelming when youre dealing with pain and fatigue every day
daily) Other health conditions that could affect your safety or suitability for treatment Cost and insurance coverage, which can vary greatly between drugs While semaglutide and tirzepatide generally show the highest average weight loss in trials, liraglutide may still be the better choice for certain patients